ŵ»ª¶à·¢ÐÔÓ²»¯ÓÖÒ»´´ÐÂÒ©ÍòÁ¢ÄÜ(R)£¨Î÷ÄáĪµÂ£©Öйú»ñÅú

·¢²¼Ê±¼ä£º2020-05-10 10:30:38 À´Ô´£º
  • Öйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼ÍòÁ¢ÄÜ®£¨Î÷ÄáĪµÂ£©ÓÃÓÚÖÎÁƳÉÈ˸´·¢ÐͶ෢ÐÔÓ²»¯
  • ĿǰȫÇòÊ׸ö¡¢Î¨Ò»ÓÃÓÚÖÎÁƻÐԼ̷¢½øÕ¹ÐͶ෢ÐÔÓ²»¯£¨SPMS£©µÄ¿Ú·þ¼²²¡ÐÞÕýÖÎÁÆ£¨DMT£©Ò©Îï[1]
  • ¸ß´ï50-60%µÄ¸´·¢»º½âÐÍ£¨RRMS£©»¼Õß½«·¢Õ¹Îª»î¶¯ÐԼ̷¢½øÕ¹ÐͶ෢ÐÔÓ²»¯£¨SPMS£©[2]£¬ÍòÁ¢ÄÜ®£¨Î÷ÄáĪµÂ£©ÄÜÓÐЧ¼õ»º»¼Õ߲м²½øÕ¹ºÍÈÏÖªÄÜÁ¦Ï½µ

ÉϺ£2020Äê5ÔÂ9ÈÕ /ÃÀͨÉç/ -- ŵ»ªÖÆÒ©£¨Öйú£©Ðû²¼£¬¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼ÍòÁ¢ÄÜ®£¨Î÷ÄáĪµÂ£©ÓÃÓÚÖÎÁƳÉÈ˸´·¢ÐͶ෢ÐÔÓ²»¯£¬°üÀ¨ÁÙ´²¹ÂÁ¢×ÛºÏÕ÷£¨CIS£©£¬¸´·¢-»º½âÐͼ²²¡£¨RRMS£©ºÍ»î¶¯ÐԼ̷¢½øÕ¹Ðͼ²²¡£¨SPMS£©¡£Ëæ×Åʱ¼äµÄÍÆÒÆ£¬¸ß´ï50-60% µÄRRMS»¼Õß½«·¢Õ¹ÎªSPMS£¬ÍòÁ¢ÄÜ®£¨Î÷ÄáĪµÂ£©ÊÇĿǰȫÇòÊ׸ö¡¢Ò²ÊÇΨһÅú×¼ÓÃÓÚÖÎÁÆSPMSµÄ¿Ú·þ¼²²¡ÐÞÕýÖÎÁÆ£¨DMT£©Ò©Î¼°Ô翪ʼÖÎÁÆ¿ÉÒÔÓÐЧ¼õ»º»¼Õ߲м²½øÕ¹ºÍÈÏÖªÄÜÁ¦Ï½µ¡£

ŵ»ªÖÆÒ©£¨Öйú£©×ܲÃÕÅӱŮʿ±íʾ£º¡°´´ÏëҽҩδÀ´ÊÇŵ»ªµÄʹÃü¡£µÃÒæÓÚÖйúÕþ¸®¼ÓËÙ´´ÐÂÒ©ÎïµÄ¾öÐĺÍÐж¯Á¦£¬Îҷdz£¸ßÐ˼ÌÈ¥Äê7Ô½ÝÁéÑÇ®£¨·Ò¸êĪµÂ£©ÔÚÖйú»ñÅú²»µ½Ò»Ä꣬ŵ»ªÔÚ¶à·¢ÐÔÓ²»¯ÁìÓòÓÖÒ»¿îÍ»ÆÆÐÔÒ©ÎïÍòÁ¢ÄÜ®£¨Î÷ÄáĪµÂ£©Ò²»ñµÃÉÏÊÐÅú×¼¡£»î¶¯ÐԼ̷¢½øÕ¹ÐÍ»¼ÕßÍùÍùÃæÁÙ¸ü¸ßµÄ²»¿ÉÄæµÄ²Ð¼²·çÏÕ£¬¼²²¡¸ºµ£ÖØ£¬Î´±»Âú×ãµÄÖÎÁÆÐèÇóÒ²¸ü´ó¡£ÍòÁ¢ÄÜ®£¨Î÷ÄáĪµÂ£©µÄµ½À´ÓÐÍûΪÕâЩ»¼ÕßÖØÐ´øÀ´Éú»îµÄÊï¹â¡£Î´À´£¬Åµ»ª»á½«¸ü¶à´´Ð¶෢ÐÔÓ²»¯ÖÎÁÆ·½°¸´øµ½Öйú£¬Ô츣»¼Õß¡£¡±

½üÁù³ÉRRMS»¼Õ߻ᷢչÖÁSPMS£¬»¼Õßȱ·¦ÓÐЧÖÎÁÆ·½·¨

¶à·¢ÐÔÓ²»¯£¨MS£©ÊÇÒ»ÖÖÂýÐÔÑ×Ö¢ÐÔ×ÔÉíÃâÒß¼²²¡£¬»¼ÕßµÄ×ÔÉíÃâÒßϵͳ¹¥»÷±£»¤Éñ¾­µÄËèÇÊ£¬µ¼ÖÂÉñ¾­¹¦ÄܵÄËðÉË£¬´ó¶àÊý»¼ÕßÔÚ20-40ËêÖ®¼ä³öÏÖÊ×´ÎÖ¢×´£¬ÊÇÔì³ÉÇà׳ÄêÉñ¾­¹¦Äܲм²×î³£¼ûÔ­ÒòÖ®Ò»¡£ÖйúµÄMS»¼²¡ÂÊԼΪ7.5/100000[3]£¬ Ô¼30000¶àÃû»¼Õß¡£Ä¿Ç°£¬MS·ÖΪÈýÖÖÖ÷ÒªÁÙ´²²¡³Ì£ºÔ­·¢½øÕ¹ÐͶ෢ÐÔÓ²»¯£¨PPMS£©¡¢¸´·¢»º½âÐͶ෢ÐÔÓ²»¯£¨RRMS£©¡¢¼Ì·¢½øÕ¹ÐͶ෢ÐÔÓ²»¯£¨SPMS£©¡£

85%¶à·¢ÐÔÓ²»¯ÊôÓÚ¸´·¢»º½âÐͶ෢ÐÔÓ²»¯¡£Èç¹ûδÄܵõ½ÓÐЧµÄÖÎÁÆ£¬Ô¼50-60%µÄRRMS»¼Õß»á½øÕ¹ÎªSPMS£¬×î¿ì5Äê¡£Ïà½ÏRRMS£¬SPMS»¼ÕßÃæÁÙ¸üÑÏÖØµÄ¹¦ÄÜË𺦣¬»¼Õß¿ÉÄܳöÏÖÐÐ×ßÀ§ÄÑ¡¢ÈÏÖªË𺦡¢ÊÓÁ¦ºÍÊÖ±Û¹¦ÄÜÊÜËð¡¢ÒÖÓô¡¢ÌÛÍ´¡¢Æ£ÀͺÍÄòʧ½ûµÈÖ¢×´£¬ÑÏÖØÓ°ÏìÈÕ³£¹¤×÷ºÍÉú»î¡£

ÍòÁ¢ÄÜ®Ê׸ö±»ÑéÖ¤ÔÚSPMS»¼ÕßÖоßÓжÀÌØÁÆÐ§µÄ¿Ú·þDMTÒ©Îï

MS²¡Òò²»Ã÷¡£Ä¿Ç°ÈÏΪMS¿ÉÄÜÊÇÒ»ÖÖÓɶàÖÖÒòËØ¹²Í¬×÷Óã¬Í¨¹ýÑ×Ö¢ºÍÃâÒßÆÆ»µ´óÄÔ¡¢ÊÓÉñ¾­ºÍ¼¹ËèÕý³£¹¦Äܵļ²²¡¡£ÍòÁ¢ÄÜ®£¨Î÷ÄáĪµÂ£©ÊÇÐÂÒ»´ú¡¢Ñ¡ÔñÐÔ1-Á×ËáÇʰ±´¼£¨S1P£©ÊÜÌåµ÷½Ú¼Á¡£Î÷ÄáεÂÌØÓеÄË«ÖØ»úÖÆ£¬Ò»·½Ãæ×èÖ¹ÁܰÍϸ°û½øÈëMS»¼ÕßÖÐÊàÉñ¾­ÏµÍ³£¬Æðµ½¿¹Ñ××÷Óã»ÁíÒ»·½ÃæÄÜÖ±½ÓÔÚÖÐÊàÉñ¾­ÏµÍ³·¢»Ó´Ù½øËèÇÊÔÙÉúÌṩÉñ¾­±£»¤×÷Óá£

ÍòÁ¢ÄÜ®µÄ»ñÅúÊÇ»ùÓÚIIIÆÚEXPANDÑо¿µÄ¿ª´´ÐÔÊý¾Ý£¬ÊÇÔڹ㷺µÄSPMS»¼ÕßȺÌ壨1651ÃûEDSSÆÀ·Ö3.0-6.5µÄSPMS»¼Õߣ©ÖпªÕ¹µÄ×î´ó¹æÄ£µÄËæ»ú¡¢Ë«Ã¤¡¢°²Î¿¼Á¶ÔÕÕÁÙ´²Ñо¿£¬ÆÀ¹ÀÁËÍòÁ¢ÄÜ®ÔÚSPMS»¼ÕßÖеij¤ÆÚÁÆÐ§ºÍ°²È«ÐÔ¡£Ñо¿½á¹ûÏÔʾ£¬ÍòÁ¢ÄÜ®ÏÔÖø½µµÍÁË3¸öÔÂÈ·Ö¤²Ð¼²½øÕ¹·çÏÕ£¨Ó밲ο¼ÁÏà±È½µµÍ21%£¬P=0.013£»ÔÚɸ²éǰ2Äê´æÔÚ¸´·¢»î¶¯ÐÔ»¼ÕßÖУ¬Ó밲ο¼ÁÏà±È½µµÍ33%£¬P=0.0100£©¡£Í¬Ê±£¬ÍòÁ¢ÄÜ®ÏÔÖø½µµÍ6¸öÔ²м²½øÕ¹·çÏÕ£¨Ó밲ο¼ÁÏà±È½µµÍ26%£¬P=0.0058£©£¬²¢½«Ä껯¸´·¢ÂʽµµÍÁË55%¡£ ͬʱ£¬ÔÚ°üÀ¨ÈÏÖª¡¢MRI¼²²¡»î¶¯ºÍÄÔÈÝÁ¿Ëðʧ£¨ÄÔήËõ£©·½ÃæÒ²±íÏÖ³ö»ý¼«µÄ½á¹û¡£

½ñÄê4Ô£¬Åµ»ª»¹ÔÚÃÀ¹úÉñ¾­²¡Ñ§Ñ§»áҽѧÔÓÖ¾¡¶Neurology¡·²¹³äÆÚ¿¯ÉÏ·¢²¼×îеÄÊý¾Ý£¬Ñо¿±íÃ÷£¬³ÖÐø½ÓÊÜÍòÁ¢ÄÜ®ÖÎÁƵÄSPMS»¼Õß·¢Éú²Ð¼²½øÕ¹ºÍÈÏÖª¼õÍ˵ķçÏÕµÍÓÚÑÓ³Ù½ÓÊÜÍòÁ¢ÄÜ®ÖÎÁƵϼÕߣ¬ÕâЩÁÙ´²ÖÎÁÆ»ñÒæ³ÖÐøÁË5Ä꣬ÏÔʾ³öÔçÆÚ¿ªÊ¼ÖÎÁƵÄÓÅÊÆ[4]¡£

ÔÚ¶à·¢ÐÔÓ²»¯ÁìÓò£¬Åµ»ªÓµÓзḻµÄ²úÆ·×éºÏ¡£Î´À´»¹½«Óиü¶à´´ÐÂÒ©ÎïÏà¼Ì»ñÅúºÍÉÏÊУ¬ÓÐÖúÓÚMS»¼Õß»ñµÃ¸üÊʺϵÄÖÎÁÆ·½°¸¡£

[1]National MS Society Brochure. Disease Modify Therapies for MS.
http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-The-MS-Disease-Modifying-Medications.pdf
[2]Antel J et al. Acta Neuropathol 2012; 123:627-38
[3]Incidence and Prevalence Database (IPD)
[4]Kappos L, et al. Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis up to 5 Years. Neurology. 2020; 94 (15 Supplement).

Ïà¹ØÈÈ´ÊËÑË÷£º
¹ØÓÚÎÒÃÇ ÁªÏµÎÒÃÇ ÈËÔ±²éѯ ÃâÔðÉùÃ÷ ÓÑÇéÁ´½Ó ¹óÖÝÍøLOGO ¹ã¸æ¿¯Àý ±¾Õ¾ÓòÃû °Ù¶ÈÐÂÎÅ